JLJianjun Li

Jianjun Li

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Jianjun Li has a total of 5 co-authors. Here are the top co-authors by number of shared publications:

  • Fangming Li

    Department of Neurology Shenzhen University, Shenzhen University General Hospital Shenzhen China

    1 shared publication
  • Jianyang Dong

    Rehabilitation Medicine Department, Neuroscience Cluster, The Fourth People's Hospital of Shenzhen, Shenzhen, China

    1 shared publication
  • Mengying Dai

    Department of Rehabilitation Shenzhen Children's Hospital Shenzhen China

    1 shared publication
  • Ting Xu

    Department of Neurology, Guangzhou First People's Hospital South China University of Technology Guangzhou China

    1 shared publication
  • Zinan Guo

    Department of Rehabilitation Shenzhen University, Shenzhen University General Hospital Shenzhen China

    1 shared publication

Latest Publications

  • Open Access

    The Targets of Deep Brain Stimulation in the Treatment of Treatment‐Resistant Depression: A Review

    by Jianyang Dong, Mengying Dai, Zinan Guo, Ting Xu, Fangming Li, Jianjun Li

    Purpose: The purpose of this review is to evaluate the current state and potential future directions of deep brain stimulation (DBS) therapy for treatment‐resistant depression (TRD), a condition that significantly impacts patients' quality of life and for which conventional treatments are often ineffective.Method: This review synthesizes evidence from clinical trials and preclinical studies published in five years, identified through PubMed searches using keywords (“Deep Brain Stimulation” OR DBS) AND (“Treatment‐Resistant Depression” OR TRD). Included studies encompassed clinical research (randomized/non‐randomized trials, cohort studies) and mechanistic preclinical studies, excluding non‐English publications and nonhuman experiments. Screening prioritized neuroanatomical targets (e.g., SCG, NAcc) and stimulation parameter optimization data. Examining the therapeutic mechanisms of DBS, the neuroanatomical targets utilized, and the clinical outcomes observed. It also discusses the challenges faced in DBS application and proposes potential technological advancements, such as closed‐loop therapy and fiber tracking technology.Finding: Preliminary evidence exists regarding the efficacy and safety of DBS in the treatment of TRD in the subcortical cingulate gyrus (SCG), nucleus accumbens (NAcc), ventral capsule/ventral striatum (VC/VS), anterior limb of the internal capsule (ALIC), and so forth. Nevertheless, the optimal stimulation target remains undetermined. The review highlights the complexity of TRD and the need for personalized treatment strategies, noting that genetic, epigenetic, and neurophysiological changes are implicated in DBS's therapeutic effects.Conclusion: In conclusion, while DBS for TRD remains an experimental therapy, it offers a unique and potentially effective treatment option for patients unresponsive to traditional treatments. The review emphasizes the need for further research to refine DBS targets and parameters, improve patient selection, and develop personalized treatment plans to enhance efficacy and safety in TRD management.